Glofitamab

Generic Name
Glofitamab
Brand Names
Columvi
Drug Type
Biotech
Chemical Formula
-
CAS Number
2229047-91-8
Unique Ingredient Identifier
06P3KLK2J8
Background

Glofitamab is a full-length bispecific monoclonal antibody with affinity for both CD20 and CD3 surface antigens found on B- and T-cells, respectively. It has a 2:1 configuration, with bivalency towards CD20 and monovalency towards CD3, and works by recruiting T-cells directly to the surface of cancerous B-cells.
...

Indication

Glofitamab is indicated in Canada for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from follicular lymphoma, or primary mediastinal B-cell lymphoma (PMBCL), who have received two or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T c...

Associated Conditions
Diffuse Large B-Cell Lymphoma (DLBCL), Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B Cell Lymphoma (PMBCL), Refractory Diffuse Large B Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Relapsed Diffuse Large B-cell Lymphoma (DLBCL), Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Associated Therapies
-
Clinical Trials
Related News

Glofitamab in Chinese Patients With R/R DLBCL

First Posted Date
2024-07-01
Last Posted Date
2024-07-01
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
20
Registration Number
NCT06481826
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

Glofitamab with Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

First Posted Date
2024-02-12
Last Posted Date
2024-11-19
Lead Sponsor
C. Babis Andreadis
Target Recruit Count
30
Registration Number
NCT06252675
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma

First Posted Date
2024-01-19
Last Posted Date
2024-11-25
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT06213311
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

First Posted Date
2024-01-05
Last Posted Date
2024-10-31
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
39
Registration Number
NCT06192888
Locations
🇺🇸

Dana Farber Cancer Institute (Data Collection and Specimen Analysis), Boston, Massachusetts, United States

🇺🇸

Mayo Clinic (Data Collection Only), Rochester, Minnesota, United States

🇺🇸

Washington University (Data Collection Only), Saint Louis, Missouri, United States

and more 7 locations

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

First Posted Date
2023-10-16
Last Posted Date
2024-12-10
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
182
Registration Number
NCT06084936
Locations
🇦🇺

Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia

🇦🇺

Royal Adelaide Hospital; Haematology Clinical Trials, Adelaide, South Australia, Australia

🇦🇺

Epworth Hospital, Richmond, Victoria, Australia

and more 59 locations

A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

First Posted Date
2023-10-10
Last Posted Date
2024-12-05
Lead Sponsor
University College, London
Target Recruit Count
99
Registration Number
NCT06071871
Locations
🇬🇧

Kings College Hospital NHS Foundation Trust, London, United Kingdom

🇬🇧

Churchill Hospital, Oxford, United Kingdom

🇬🇧

University College London Hospitals NHS Foundation Trust, London, United Kingdom

and more 1 locations

Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

First Posted Date
2023-09-26
Last Posted Date
2024-10-02
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
40
Registration Number
NCT06054776
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

Phase 2
Not yet recruiting
Conditions
Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
Drug: glofitamab
First Posted Date
2023-09-22
Last Posted Date
2024-03-12
Lead Sponsor
University Health Network, Toronto
Target Recruit Count
40
Registration Number
NCT06050694
Locations
🇨🇦

Princess Margaret Cancer Centre, Toronto, Ontario, Canada

A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation

First Posted Date
2023-09-21
Last Posted Date
2024-05-28
Lead Sponsor
Christine Ryan
Target Recruit Count
66
Registration Number
NCT06043674
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

First Posted Date
2023-09-21
Last Posted Date
2024-11-25
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1130
Registration Number
NCT06047080
Locations
🇩🇪

Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Germany

🇺🇸

Kaiser Permanente Medical Ctr, Vallejo, California, United States

🇺🇸

St. Luke's Hospital, Chesterfield, Missouri, United States

and more 236 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy